Please login to the form below

Not currently logged in
Email:
Password:

FDA accepts new diabetes compound NDA

The US FDA has accepted a new drug application for dapagliflozin, an investigational type 2 diabetes compound, from AstraZeneca and Bristol-Myers Squibb

The US Food and Drug Administration (FDA) has accepted for review a new drug application (NDA) for dapagliflozin, an investigational type 2 diabetes compound, from AstraZeneca (AZ) and Bristol-Myers Squibb (BMS). The European Medicines Agency (EMA) has also validated a marketing authorisation application (MAA) for the compound. 

Both submissions include data gathered during a two-year period from a global development programme involving approximately 6,000 individuals in 40 clinical studies. To comply with FDA guidelines, the US submission also includes data assessing the cardiovascular safety of dapagliflozin in adults with type 2 diabetes.

Dapagliflozin is designed to help control glycaemia independently of insulin pathways. It works by inhibiting sodium-glucose cotransporter-2 (SGLT2) – a specific target located in the kidney, leading to the excretion of excess glucose and associated calories in the urine.

The development of dapagliflozin is the result of a collaboration deal formed between AZ and BMS in 2007 to enable the companies to research, develop and commercialise select investigational drugs for type 2 diabetes.

According to the International Diabetes Federation (IDF), around 285 million people globally have diabetes. This figure is projected to increase to 438m by 2030.

8th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics